BACKGROUND Gastric cancer(GC)is a malignant tumor originating from gastric mucosal epithelial cells that has high morbidity and mortality.microRNAs(miR)are important diagnostic markers and therapeutic targets in this ...BACKGROUND Gastric cancer(GC)is a malignant tumor originating from gastric mucosal epithelial cells that has high morbidity and mortality.microRNAs(miR)are important diagnostic markers and therapeutic targets in this disease.AIM To explore the mechanism of miR-125a-5p in the pathogenesis of GC.METHODS The expression levels of miR-125a-5p,SERPINE1 and DNMT1 in GC cells and tissues were detected by real-time polymerase chain reaction(PCR)and Western blotting.Methylation-specific PCR was used to detect the level of miR-125a-5p methylation.A cell counting kit 8 assay,scratch test,and a Transwell assay were performed to detect the proliferation,migration,and invasiveness of HGC27 cells,respectively.The expression of the epithelial mesenchymal transition(EMT)-related proteins E-cadherin,N-cadherin and vimentin in HGC27 cells was detected by Western blotting,while the expression of vimentin was detected by immunofluorescence.RESULTS This study revealed that miR-125a-5p was expressed at low levels in GC clinical samples and cells and that miR-125a-5p overexpression inhibited the proliferation,migration,invasiveness and EMT of GC cells.Mechanistically,miR-125a-5p can reduce GC cell proliferation,promote E-cadherin expression,inhibit N-cadherin and vimentin expression,and reduce the EMT of GC cells,thus constraining GC cells to a certain extent.Moreover,DNMT1 inhibited miR-125a-5p expression by increasing the methylation of the miR-125a-5p promoter,thereby promoting the expression of SERPINE1,which acts together with miR-125a-5p to exert antagonistic effects on GC.CONCLUSION Our study revealed that DNMT1 promoted SERPINE1 protein expression by inducing miR-125a-5p methylation,which led to the proliferation,migration and occurrence of EMT in GC cells.展开更多
目的探讨超声引导下^(125)I粒子植入联合化疗治疗阴道残端复发性卵巢癌的临床疗效与安全性,并评价其对患者生活质量的影响。方法回顾性分析2010年1月—2023年12月哈尔滨医科大学附属肿瘤医院收治的54例阴道残端复发性卵巢癌患者临床资料...目的探讨超声引导下^(125)I粒子植入联合化疗治疗阴道残端复发性卵巢癌的临床疗效与安全性,并评价其对患者生活质量的影响。方法回顾性分析2010年1月—2023年12月哈尔滨医科大学附属肿瘤医院收治的54例阴道残端复发性卵巢癌患者临床资料,按治疗方式分为研究组(^(125)I粒子植入联合化疗,27例)与对照组(单纯化疗,27例)。两组均采用紫杉醇联合卡铂标准化疗方案,随访至治疗后12个月。比较两组患者的近期客观缓解率(objective remission rate,ORR)和疾病控制率(disease control rate,DCR),以及肿瘤标志物(CEA、CA125)水平、靶病灶大小、疼痛缓解情况、卡氏功能状态(Karnofsky performance status,KPS)评分、生命质量测定量表(functional assessment of cancer therapy,FACT-O)评分及不良反应发生情况。结果治疗后,研究组ORR显著高于对照组(100.00%vs.40.74%,P<0.001);两组DCR差异无统计学意义(100.00%vs.85.19%,P=0.119)。治疗后3、6、9、12个月,研究组CEA、CA125水平均显著低于对照组(P<0.001);治疗后9、12个月,研究组靶病灶平均最大径显著小于对照组(P<0.01)。研究组疼痛缓解率(92.00%)高于对照组(72.00%),但差异无统计学意义(P=0.141);治疗后12个月KPS评分及FACT-O总体评分均优于对照组(P=0.034)。两组患者治疗相关不良反应主要包括发热、腹痛及恶心呕吐等,其中研究组分别为发热1例、腹痛2例和恶心呕吐1例,对照组发热2例、腹痛1例和恶心呕吐2例,且均未出现严重不良事件。结论超声引导下^(125)I粒子植入联合化疗可显著提高阴道残端复发性卵巢癌局部肿瘤缓解率,改善患者功能状态及生活质量,且安全性良好,可作为该类患者的一种有效个体化治疗选择。展开更多
基金the Research Program of the Science and Technology Department of Yunnan Province,No.202101AY070001-204.
文摘BACKGROUND Gastric cancer(GC)is a malignant tumor originating from gastric mucosal epithelial cells that has high morbidity and mortality.microRNAs(miR)are important diagnostic markers and therapeutic targets in this disease.AIM To explore the mechanism of miR-125a-5p in the pathogenesis of GC.METHODS The expression levels of miR-125a-5p,SERPINE1 and DNMT1 in GC cells and tissues were detected by real-time polymerase chain reaction(PCR)and Western blotting.Methylation-specific PCR was used to detect the level of miR-125a-5p methylation.A cell counting kit 8 assay,scratch test,and a Transwell assay were performed to detect the proliferation,migration,and invasiveness of HGC27 cells,respectively.The expression of the epithelial mesenchymal transition(EMT)-related proteins E-cadherin,N-cadherin and vimentin in HGC27 cells was detected by Western blotting,while the expression of vimentin was detected by immunofluorescence.RESULTS This study revealed that miR-125a-5p was expressed at low levels in GC clinical samples and cells and that miR-125a-5p overexpression inhibited the proliferation,migration,invasiveness and EMT of GC cells.Mechanistically,miR-125a-5p can reduce GC cell proliferation,promote E-cadherin expression,inhibit N-cadherin and vimentin expression,and reduce the EMT of GC cells,thus constraining GC cells to a certain extent.Moreover,DNMT1 inhibited miR-125a-5p expression by increasing the methylation of the miR-125a-5p promoter,thereby promoting the expression of SERPINE1,which acts together with miR-125a-5p to exert antagonistic effects on GC.CONCLUSION Our study revealed that DNMT1 promoted SERPINE1 protein expression by inducing miR-125a-5p methylation,which led to the proliferation,migration and occurrence of EMT in GC cells.
文摘目的探讨超声引导下^(125)I粒子植入联合化疗治疗阴道残端复发性卵巢癌的临床疗效与安全性,并评价其对患者生活质量的影响。方法回顾性分析2010年1月—2023年12月哈尔滨医科大学附属肿瘤医院收治的54例阴道残端复发性卵巢癌患者临床资料,按治疗方式分为研究组(^(125)I粒子植入联合化疗,27例)与对照组(单纯化疗,27例)。两组均采用紫杉醇联合卡铂标准化疗方案,随访至治疗后12个月。比较两组患者的近期客观缓解率(objective remission rate,ORR)和疾病控制率(disease control rate,DCR),以及肿瘤标志物(CEA、CA125)水平、靶病灶大小、疼痛缓解情况、卡氏功能状态(Karnofsky performance status,KPS)评分、生命质量测定量表(functional assessment of cancer therapy,FACT-O)评分及不良反应发生情况。结果治疗后,研究组ORR显著高于对照组(100.00%vs.40.74%,P<0.001);两组DCR差异无统计学意义(100.00%vs.85.19%,P=0.119)。治疗后3、6、9、12个月,研究组CEA、CA125水平均显著低于对照组(P<0.001);治疗后9、12个月,研究组靶病灶平均最大径显著小于对照组(P<0.01)。研究组疼痛缓解率(92.00%)高于对照组(72.00%),但差异无统计学意义(P=0.141);治疗后12个月KPS评分及FACT-O总体评分均优于对照组(P=0.034)。两组患者治疗相关不良反应主要包括发热、腹痛及恶心呕吐等,其中研究组分别为发热1例、腹痛2例和恶心呕吐1例,对照组发热2例、腹痛1例和恶心呕吐2例,且均未出现严重不良事件。结论超声引导下^(125)I粒子植入联合化疗可显著提高阴道残端复发性卵巢癌局部肿瘤缓解率,改善患者功能状态及生活质量,且安全性良好,可作为该类患者的一种有效个体化治疗选择。
